Premium
Heparanase expression in Langerhans cell histiocytosis
Author(s) -
Dvir Rina,
Vlodavsky Israel,
Ilan Neta,
Bitan Menachem,
Issacov Josephine,
Elhasid Ronit
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25046
Subject(s) - heparanase , heparan sulfate , medicine , immunohistochemistry , langerhans cell histiocytosis , angiogenesis , histiocytosis , pathology , cancer research , pathogenesis , immunology , disease , heparin
Heparanase is an endo‐beta D ‐glucuronidase capable of cleaving heparan sulfate side chains, yielding heparan sulfate fragments. Heparanase activity has been correlated with the metastatic potential of tumor‐derived cells, angiogenesis, autoimmunity and inflammation. We performed a study of heparanase expression in specimens obtained from patients with Langerhans cell histiocytosis (LCH). Paraffin embedded slides from 25 patients were studied by immunohistochemistry for heparanase. Most patients had positive staining for heparanase (21/25). There was no positive association with severity of disease and other clinical characteristics. Further studies are required to clarify the role of heparanase in the pathogenesis of LCH. Pediatr Blood Cancer 2014; 61:1883–1885. © 2014 Wiley Periodicals, Inc.